Pds Biotechnology Corp. (PDSB) intrinsic value & 10-year financials
Pds Biotechnology Corp. (PDSB) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.13
- Market cap
- $52.4M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 791.2%
- Free cash flow (FY2025)
- -$27.8M
PDSB 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$34.5M | -$0.74 | -$27.8M | — | 152.3% |
| FY2024 | — | -$37.6M | -$1.03 | -$35.1M | — | 134.1% |
| FY2023 | — | -$42.9M | -$1.39 | -$33.6M | — | 139.0% |
| FY2022 | — | -$40.9M | -$1.43 | — | — | 257.4% |
| FY2021 | — | -$16.9M | -$0.66 | — | — | 1120.5% |
| FY2020 | — | -$14.8M | -$0.89 | — | — | 1770.2% |
| FY2019 | — | -$7.0M | — | — | — | 4533.0% |
| FY2018 | — | -$40.9M | — | -$33.2M | — | -87.5% |
| FY2017 | — | -$50.9M | — | -$40.9M | — | -65.2% |
| FY2016 | — | -$38.8M | — | -$32.9M | — | -42.2% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
PDS Biotechnology Corp revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
PDS Biotechnology Corp has earned high returns on invested capital, averaging 15.7% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
PDS Biotechnology Corp capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
PDS Biotechnology Corp is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.